Basilard Biotech is a Southern-California-based company poised to lead a revolution in the engineering of cell based therapies in Cell and Gene Therapy (CGT). In 2019, the company launched a disruptive gene delivery technology platform called SoloPore™. This novel approach to nanomechanical gene delivery has the potential to disrupt the current limitations of current viral and non-viral gene delivery—a breakthrough that could facilitate better scalability and more cost-effective production of cell and gene therapies.
In this interview with Brynley Lee, CEO of Basilard, we learn about the formation of Basilard Biotech, explore the company’s novel SoloPore™ technology, dive into the company’s funding strategy, and explore its future goals. Enjoy! [Read more…]